NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/11/2025
Voltar para busca
Dado oficial do USPTO
ONE-STOP-SITE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ONE-STOP-SITE
ST13
US500000079295569Classe
1, 5, 42
Pedido
79295569
Registro
6458312
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
24
Atualização mais recente
08/11/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
02/06/2020
Data de registro
24/08/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/08/2021
Última transação
08/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
IE
Examinador
SABLE, ERIC
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Hovione Scientia Limited
Representantes
R. Peter Spies DTL LIMITED
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Active chemical ingredients for use in the manufacture of pharmaceuticals for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disordersall of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals
Classe 5
Compositions for medical and veterinarian usechemical products for pharmaceutical usechemical preparations for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disordersall of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical usechemical preparations for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disordersall of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals; pharmaceutical active ingredientssold as a component ingredient of pharmaceutical preparationspharmaceutical preparations and compoundsall of the foregoing for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disorders; all of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals
Classe 42
Development of pharmaceutical products and drug products; research on pharmaceutical products and drug products; research and development of new products in the pharmaceutical industry; Consulting services in the field of design and development of engineering processes for the pharmaceutical industry; research and development services in the pharmaceutical field; research and development services in the field of pharmaceuticalschemical preparationsvaccinesmedicinesantibodiesnew products in the medical field
Publicações
Histórico de despachos e eventos da marca no USPTO.
24 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/05/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/02/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/02/2022
FIMP
FINAL DISPOSITION PROCESSED
03/02/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/11/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
24/08/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/06/2021
PUBO
PUBLISHED FOR OPPOSITION
08/06/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/05/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/05/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/05/2021
RFNT
REFUSAL PROCESSED BY IB
29/11/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/11/2020
RFRR
REFUSAL PROCESSED BY MPU
05/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
20/10/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/10/2020
CNRT
NON-FINAL ACTION WRITTEN
15/10/2020
DOCK
ASSIGNED TO EXAMINER
14/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ONE-STOP-SITE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.